undamentalytics Newsletter
Sign in

Lexicon Pharmaceuticals, Inc. income statement

In fiscal 2025, Lexicon Pharmaceuticals, Inc. reported revenue of $49.8m, up 60.2% on the year before, operating income of −$48.9m (a -98.2% margin) and net income of −$50.3m, or −$0.14 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1152122313079926332224001315041
Cost of revenue———————02232000100
Gross profit———————79906131922001305041
Research and development8179928390899516415210092154555359846160
Selling, general and administrative————————————32481141433735
General and administrative191917171719244366645747——————
Operating income−90−96−114−108−102−1001−127−131−103141−48−87−101−172−197−49−55
Interest expense33322277721211513————
Income before tax−93−102−116−110−104−100−5−131−136−121124−59−88—————
Income tax−0−0000−000————0000——
Net income−83−102−116−110−104−100−5−131−123−121130−59−88−102−177−200−50−61
Diluted EPS−$0.57−$2.38−$2.38−$1.61−$1.42−$1.31−$0.05−$1.27−$1.17−$1.14$1.16−$0.53−$0.60−$0.62−$0.80−$0.63−$0.14−$0.16
Diluted shares (average)—43m49m70m73m76m104m104m105m106m117m111m146m166m221m320m363m391m
EBITDA−84−90−109−104−100−982−125−127−100145−45−87−100−171−197−48−54

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CUE vs LXRXLXRX vs STROLXRX vs ZYME

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lexicon Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lexicon Pharmaceuticals, Inc.